• 1
    Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. WHO Technical Report Series 843. Geneva, Switzerland: WHO; 1994.
  • 2
    Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:113741.
  • 3
    Hagino H, Katagiri H, Okano T, Yamamoto K, Teshima R. Increasing incidence of hip fracture in Tottori Prefecture, Japan: trend from 1986 to 2001. Osteoporos Int. 2005;16:19638.
  • 4
    Hagino H, Furukawa K, Fujiwara S, Okano T, Katagiri H, Yamamoto K, Teshima R. Recent trends in the incidence and lifetime risk of hip fracture in Tottori. Japan. Osteoporos Int. 2009;20:5438.
  • 5
    Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone. 2003;32:46873.
  • 6
    Hasegawa Y, Suzuki S, Wingstrand H. Risk of mortality following hip fracture in Japan. J Orthop Sci. 2007;12:1137.
  • 7
    Hagino H. Cost-effectiveness of the treatment for osteoporosis. Nippon Rinsho. 2002;60:64554. Japanese.
  • 8
    Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011;40:27584.
  • 9
    Johnell O, Jönsson B, Jönsson L, Black D. Cost-effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003;21:30514.
  • 10
    Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2002;6:1146.
  • 11
    Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9:1160.
  • 12
    Ström O, Borgström F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int. 2007;18:104761.
  • 13
    Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142:73441.
  • 14
    Committee of Japanese Guidelines for the Prevention and Treatment of Osteoporosis. The Japanese guidelines for the prevention and treatment of osteoporosis (2011 edition). Tokyo, Japan: Life Science Publishing; Japanese. 2012.
  • 15
    Ross PD, Fujiwara S, Huang C, Davis JW, Epstein RS, Wasnich RD, Kodama K, Melton LJ 3rd. Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol. 1995;24:11717.
  • 16
    Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M. Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res. 2003;18:154753.
  • 17
    Ross PD, Norimatsu H, Davis JW, Yano K, Wasnich RD, Fujiwara S, Hosoda Y, Melton LJ 3rd. A comparison of hip fracture incidence among native Japanese, Japanese Americans, and American Caucasians. Am J Epidemiol. 1991;15:8019.
  • 18
    Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001;19:3317.
  • 19
    Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:46889.
  • 20
    Drummond MF, McGuire A. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press; 2001.
  • 21
    De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA., Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ. 1997;315:2215.
  • 22
    Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:37582.
  • 23
    Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ 3rd, Pols HA, Reeve J, Silman AJ, Tenenhouse A. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004;35:102937.
  • 24
    Kanis JA, Johansson H, Johnell O, Oden A, De Laet C. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16:73742.
  • 25
    Kanis JA, Johnell O, Oden A, Johansson H, De Laet C. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16:15562.
  • 26
    Japan Ministry of Health, Labour, and Welfare. Life table for Japanese [Internet]. Tokyo, Japan: Japan Ministry of Health, Labour, and Welfare; [cited 2012 Sep 17]. Available from: Japanese. 2005.
  • 27
    Tsuboi M, Hasegawa Y, Suzuki S, Wingstrand H, Thorngren KG. Mortality and mobility after hip fracture in Japan: a ten-year follow-up. J Bone Joint Surg Br. 2007;89:4616.
  • 28
    Hayashi Y. Economical view-point for treatment of osteoporosis. Nippon Rinsho. 2007;65:60914. Japanese.
  • 29
    Tosteson AN, Jönsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int. 2001;12:84957.
  • 30
    National Health Insurance Price List. Tokyo, Japan: Jihou Press; Japanese. 2010.
  • 31
    Medical Fee Schedule. Tokyo, Japan: Igaku-tsushin-sya; Japanese. 2010.
  • 32
    Kondo A, Zierler BK, Isokawa Y, Hagino H, Ito Y. Comparison of outcomes and costs after hip fracture surgery in three hospitals that have different care systems in Japan. Health Policy. 2009;91:20410.
  • 33
    Reward for nursing care. Tokyo, Japan: Igaku-tsushin-sya; Japanese. 2009.
  • 34
    Nawata S, Yamada Y, Ikeda S, Ikegami N. EuroQol Study of the Elderly General Population: relationship with IADL and other attributes. Iryo To Shakai. 2000;10:7586. Japanese.
  • 35
    Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R. Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int. 2009;20:695702.
  • 36
    Imai H, Fujii Y, Fukuda Y, Nakao H, Yahata Y. Health-related quality of life and beneficiaries of long-term care insurance in Japan. Health Policy. 2008;85:34955.
  • 37
    Ström O, Borgström F, Kanis JA, Jönsson B. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int. 2009;20:2334.
  • 38
    Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL. National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:43747.
  • 39
    FRAX WHO Fracture Risk Assessment Tool. Japan - The probabilities of a major osteoporotic fracture in women [Internet]. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; [cited 2012 Sep 17]. Available from:
  • 40
    Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA. Development and application of a Japanese model of the WHO Fracture Risk Assessment tool (FRAX™). Osteoporos Int. 2008;19:42935.
  • 41
    Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62:2091100.
  • 42
    National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal [Internet]. London, UK: National Institute for Clinical Excellence; [cited 2012 Sep 17]. Available from: 2008.
  • 43
    Ohkusa Y, Sugawara T. Research for willingness to pay for one QALY gain. Iryo To Shakai. 2006;16:15765. Japanese.